{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:27:40Z","timestamp":1776400060527,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"International talent training program of Shanghai Xinhua Hospital","award":["2023YGJRC04"],"award-info":[{"award-number":["2023YGJRC04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Although aspirin was reported to have primary thromboprophylactic efficacy on cancer patients, its adjuvant role in the treatment of patients with cancer-associated venous thromboembolism (VTE) has been unclear yet.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with cancer-associated VTE were retrospectively analyzed and divided into aspirin group and non-aspirin group based on whether they underwent low-dose aspirin (100 mg daily) in addition to conventional anticoagulants. Propensity score matching was used to balance baseline characteristics between the aspirin group and non-aspirin group in a 1:2 ratio. The primary, secondary, and tertiary outcomes were VTE recurrence, mortality and major bleeding, and net clinical benefit (NCB), at 6 months after VTE diagnosis, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The VTE recurrence occurred in 13 (3.1%) in the aspirin group (<jats:italic>N<\/jats:italic>\u2009=\u2009423) and 55 (6.5%) in the non-aspirin group (<jats:italic>N<\/jats:italic>\u2009=\u2009846) (hazard ratio [HR] 0.546, 95% confidence interval [CI] [0.298\u20130.988], <jats:italic>P<\/jats:italic>\u2009=\u20090.011). The PE-related mortality occurred in 12 (2.8%) in the aspirin group and 46 (5.4%) in the non-aspirin group (HR 0.535, 95% CI [0.283\u20130.909], <jats:italic>P<\/jats:italic>\u2009=\u20090.037). The all-cause mortality occurred in 108 (25.5%) in the aspirin group and 228 (27.0%) in the non-aspirin group (HR 0.983, 95% CI [0.782\u20131.237], <jats:italic>P<\/jats:italic>\u2009=\u20090.887). The major bleeding occurred in 52 (12.3%) in the aspirin group and 46 (5.4%) in the non-aspirin group (HR 2.448, 95% CI [1.646\u20133.641], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The NCB occurred in 274 (64.8%) in the aspirin group and 554 (65.5%) in the non-aspirin group (HR 0.976, 95% CI [0.801\u20131.189], <jats:italic>P<\/jats:italic>\u2009=\u20090.812).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>For patients with cancer-associated VTE, the adjuvant use of low-dose aspirin based on conventional anticoagulants improves VTE recurrence and PE-related mortality, compared with isolated use of anticoagulants, whereas it does not improve all-cause mortality or net clinical benefit. Adjuvant low-dose aspirin use is associated with an increased risk of bleeding.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12916-025-04284-8","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:18:54Z","timestamp":1753741134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adjuvant therapeutic efficacy of low-dose aspirin on short-term outcomes of patients with cancer-associated venous thromboembolism"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-8535","authenticated-orcid":false,"given":"Wei","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengfeng","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"5","key":"4284_CR1","first-page":"409","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409\u201336.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"4284_CR2","first-page":"1181","volume":"19","author":"MB Streiff","year":"2021","unstructured":"Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(10):1181\u2013201.","journal-title":"J Natl Compr Canc Netw."},{"issue":"7","key":"4284_CR3","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334\u201347.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4284_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496\u2013520.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4284_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023;34(5):452\u201367.","journal-title":"Ann Oncol"},{"issue":"1","key":"4284_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/jth.12070","volume":"11","author":"D Farge","year":"2013","unstructured":"Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11(1):56\u201370.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"4284_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/1074248420925021","volume":"25","author":"P Li","year":"2020","unstructured":"Li P, Ning Y, Li M, et al. Aspirin is associated with reduced rates of venous thromboembolism in older patients with cancer. J Cardiovasc Pharmacol Ther. 2020;25(5):456\u201365.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"10","key":"4284_CR8","first-page":"1213","volume":"15","author":"G Curigliano","year":"2007","unstructured":"Curigliano G, Balduzzi A, Cardillo A, et al. Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. Support Care Cancer. 2007;15(10):1213\u20137.","journal-title":"Support Care Cancer"},{"issue":"11","key":"4284_CR9","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","volume":"382","author":"TG Simon","year":"2020","unstructured":"Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med. 2020;382(11):1018\u201328.","journal-title":"N Engl J Med"},{"issue":"9826","key":"4284_CR10","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602\u201312.","journal-title":"Lancet"},{"issue":"9826","key":"4284_CR11","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591\u2013601.","journal-title":"Lancet"},{"issue":"6","key":"4284_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jama.2009.1112","volume":"302","author":"AT Chan","year":"2009","unstructured":"Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649\u201358.","journal-title":"JAMA"},{"issue":"21","key":"4284_CR13","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","volume":"367","author":"TA Brighton","year":"2012","unstructured":"Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979\u201387.","journal-title":"N Engl J Med"},{"key":"4284_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5133","volume":"347","author":"LA Castellucci","year":"2013","unstructured":"Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ. 2013;347: f5133.","journal-title":"BMJ"},{"issue":"17","key":"4284_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599\u2013607.","journal-title":"N Engl J Med"},{"issue":"4","key":"4284_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543\u2013603.","journal-title":"Eur Heart J"},{"issue":"6","key":"4284_CR17","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545\u2013608.","journal-title":"Chest"},{"issue":"4","key":"4284_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927\u201374.","journal-title":"Blood Adv"},{"issue":"3","key":"4284_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/eurheartj\/ehab816","volume":"43","author":"FA Klok","year":"2022","unstructured":"Klok FA, Ageno W, Ay C, et al. Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. Eur Heart J. 2022;43(3):183\u20139.","journal-title":"Eur Heart J"},{"issue":"22","key":"4284_CR20","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1182\/bloodadvances.2018024828","volume":"2","author":"W Lim","year":"2018","unstructured":"Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226\u201356.","journal-title":"Blood Adv"},{"issue":"6","key":"4284_CR21","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/jth.14769","volume":"18","author":"T Tritschler","year":"2020","unstructured":"Tritschler T, Kraaijpoel N, Girard P, et al. Definition of pulmonary embolism-related death and classification of the cause of death in venous thromboembolism studies: communication from the SSC of the ISTH. J Thromb Haemost. 2020;18(6):1495\u2013500.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"4284_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost"},{"issue":"9596","key":"4284_CR23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"2","key":"4284_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/sim.8399","volume":"39","author":"PC Austin","year":"2020","unstructured":"Austin PC, Latouche A, Fine JP. A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model. Stat Med. 2020;39(2):103\u201313.","journal-title":"Stat Med"},{"issue":"5","key":"4284_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/jama.2019.21558","volume":"323","author":"L Thomas","year":"2020","unstructured":"Thomas L, Li F, Pencina M. Using propensity score methods to create target populations in observational clinical research. JAMA. 2020;323(5):466\u20137.","journal-title":"JAMA"},{"issue":"2","key":"4284_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150\u201361.","journal-title":"Pharm Stat"},{"issue":"23","key":"4284_CR27","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.2106\/JBJS.17.00253","volume":"99","author":"GM Mendez","year":"2017","unstructured":"Mendez GM, Patel YM, Ricketti DA, Gaughan JP, Lackman RD, Kim TWB. Aspirin for prophylaxis against venous thromboembolism after orthopaedic oncologic surgery. J Bone Joint Surg Am. 2017;99(23):2004\u201310.","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"4284_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.thromres.2010.04.005","volume":"126","author":"N Konishi","year":"2010","unstructured":"Konishi N, Hiroe K, Kawamura M. Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. Thromb Res. 2010;126(2):124\u20139.","journal-title":"Thromb Res"},{"issue":"1","key":"4284_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/ijc.32083","volume":"145","author":"KKF Tsoi","year":"2019","unstructured":"Tsoi KKF, Ho JMW, Chan FCH, Sung JJY. Long-term use of low-dose aspirin for cancer prevention: a 10-year population cohort study in Hong Kong. Int J Cancer. 2019;145(1):267\u201373.","journal-title":"Int J Cancer"},{"issue":"20","key":"4284_CR30","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1001\/jama.2024.4840","volume":"331","author":"WY Chen","year":"2024","unstructured":"Chen WY, Ballman KV, Partridge AH, et al. Aspirin vs placebo as adjuvant therapy for breast cancer: the Alliance A011502 randomized trial. JAMA. 2024;331(20):1714\u201321.","journal-title":"JAMA"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04284-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04284-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04284-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:48:56Z","timestamp":1757310536000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04284-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4284"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04284-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"2 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study protocol was approved by the institutional review board of Shanghai Xinhua Hospital (approval number: XHEC-QT-2021\u2013056). Written informed consent from the participants or their next of kin was waived due to: (1) the study involves no more than minimal risk for patients; (2) the study cannot adversely affect the rights and welfare of patients; (3) the study cannot be performed without the exemption of informed consent of patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"444"}}